MHealth to Enhance & Sustain Drug Use Reduction of the QUIT BI in Primary Care

Launched by UNIVERSITY OF CALIFORNIA, LOS ANGELES · Jun 14, 2021

Keywords

ClinConnect Summary

The QUIT-Mobile study is looking at how using mobile phones can help people reduce risky drug use over a year. This trial builds on a previous program called the Quit Using Drugs Intervention Trial (QUIT), which has already shown success in helping people cut back on drug use. Participants will be adults, mostly Latino, who visit certain clinics in Southern California and have been identified as having moderate drug use. They will be divided into three groups to see how well the mobile phone support compares to standard care and usual care over the course of 12 months.

To be eligible for the study, participants need to be at least 18 years old, have a phone for follow-up calls, speak either English or Spanish, and have a specific score indicating moderate drug use. They also need to be planning to stay in the Los Angeles area for the duration of the study. Participants can expect to engage with health coaches through phone calls and receive feedback via mobile technology to help them stay on track with reducing their drug use. It's important to note that pregnant women and those with severe substance use issues are not eligible for this study. Overall, the goal is to find effective ways to support individuals in maintaining their progress in reducing drug use.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients 18 years old and older receiving care at study clinics.
• • Have a phone number at which they can be contacted over time during the study (to conduct follow-up health education phone calls).
• • Have a primary care visit with a regular clinic provider on the date of recruitment and enrollment.
• • English or Spanish-speaking.
• • ASSIST score between 4 and 26 indicating risky (moderate) drug use, and used the substance in the past 30 days.
• • Able (not cognitively impaired) and willing to cooperate with data collection and research procedures, including and 2-week, 6-week, and 3, 6, 12-month follow-up assessments.
• • Planning to be in the Los Angeles area for the next 12 months so they can complete the study period.
• Exclusion Criteria:
• • Pregnancy: Women who report being pregnant at the time of randomization will be excluded from participation. This latter exclusion criterion is based on the following reasons: (a) The interaction of drug use (in any amount) and fetal-maternal health is physiologically complex and beyond the scope of this proposed intervention. (b) Drug users who are pregnant are considered high-risk pregnancies.
• • Repeaters: All patients will be asked a set of repeater questions. This includes a question on whether they have ever been involved in our UCLA study at the clinic before. We will create a unique identifier based on a set of questions that we have used in our prior studies that combines aspects about the potential subject (mother's first name, father's first name, month and day of birth) that will screen them out if they screen again in the future.
• • ASSIST Score above 26 indicating high use and potential serious SUD needing referral to specialty treatment: The RA will receive a message that the subject scored 27+ on alcohol or any drugs on the WHO ASSIST (i.e. indication of possible severe substance use disorder). The RA will inform the patient that they are at risk for certain health behaviors and ask the patient if they want to disclose this information to their doctor. If they agree to disclose information to their doctor then we will fill out a letter informing the doctor of patient's potential more serious substance use disorder. We will also provide the patient with a list of local substance use disorder treatment referrals.
• • ASSIST Score below 4 (low use): These patients are not eligible for enrollment in the trial.
• • Subject Enrolled in a Substance Use Treatment Program: Subjects enrolled in a treatment program are excluded from the study.